WHO recommends COVID-19 drug and urges transparency around pricing
WHO announced on Friday in Geneva that it has strongly recommended use of nirmatrelvir and ritonavir, sold under the name Paxlovid, for mild and moderate COVID-19 patients at the highest risk of hospital admission. The oral antiretroviral drug was developed by Pfizer and is “the best therapeutic choice for high-risk patients to date,” the UN agency said. “However, availability, lack…
Read More
